ARTICLE | Clinical News
AB's AD candidate meets Phase II endpoint
September 30, 2010 12:56 AM UTC
AB Science S.A. (Euronext:AB) said masitinib met the primary endpoint of significantly improving ADAS-Cog scores from baseline to week 24 vs. placebo in a Phase II trial to treat Alzheimer's disease (...